Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A phase II, multicenter, open-label, single-arm study to evaluate the efficacy, safety and
pharmacokinetics of SC10914 in subjects with gBRCA1/2 mutated advanced ovarian cancer in
china.